Replies to post #53733 on Biotech Values

[DewDiligence]

>The impediment is reimbursement.<

That’s normally the case in Europe when it comes to off-label use. I’m saying that Atripla will prove to be an exception because Truvada+Sustiva is widely used in the first-line setting.